Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks

Stock Research Monitor: RIGL, FOLD, and AMPE

LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Ampio Pharmaceuticals Inc. (NYSE AMER: AMPE). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Rigel Pharmaceuticals

On Thursday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. recorded a trading volume of 1.43 million shares. The stock ended at $2.85, declining 2.06% from the last trading session. The Company’s shares have gained 1.42% in the last twelve months. The stock is trading below its 50-day moving average by 20.89%. Furthermore, shares of Rigel Pharma, which engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases, have a Relative Strength Index (RSI) of 29.56. Get the full research report on RIGL for free by clicking below at:

www.wallstequities.com/registration/?symbol=RIGL

Sarepta Therapeutics

Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc.’s stock finished yesterday’s session 3.47% higher at $133.75. A total volume of 2.72 million shares was traded, which was above their three months average volume of 1.75 million shares. The Company’s shares have gained 41.62% in the last month, 80.52% over the previous three months, and 295.01% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 37.89% and 93.63%, respectively. Furthermore, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases, have an RSI of 65.98.

On June 21st, 2018, research firm Robert W. Baird reiterated its ‘Outperform’ rating on the Company’s stock with an increase of the target price from $120 a share to $202 a share. To experience our free membership services anytime/ anywhere and access the free report on SRPT, click to register at:

www.wallstequities.com/registration/?symbol=SRPT

Amicus Therapeutics

At the close of trading on Thursday, shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. saw a rise of 2.99%, ending the day at $15.50. The stock recorded a trading volume of 2.11 million shares. The Company’s shares have advanced 58.81% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.93% and 5.77%, respectively. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have an RSI of 46.74. Join our big investor community at Wall St. Equities today and get your free report on FOLD at:

www.wallstequities.com/registration/?symbol=FOLD

Ampio Pharmaceuticals

Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.’s shares ended the day 0.90% higher at $2.24 with a total trading volume of 625,562 shares. The stock has gained 17.89% in the last month and 320.82% over the last twelve months. The Company’s shares are trading above their 200-day moving average by 3.64%. Additionally, shares of Ampio Pharma, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 58.17. Know more about AMPE in our free research coverage at:

www.wallstequities.com/registration/?symbol=AMPE

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 504107